Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia — Sachs 20th Annual Biotech in Europe Forum 2020
20 slides from Vivesto Ab's conference presentation, Sep 24, 2020
Slide 1: Sachs 20th Annual Biotech in Europe Forum
SACHS 20TH ANNUAL BIOTECH IN EUROPE FORUM F.R. Martelet, M.D., CEO 21 – 24th September 2020 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company Founded in 1999 NASDAQ Stockholm 2010 HQ Uppsala, Sweden Market Cap approx. SEK 2,1 B 26* employees XR-17™ technology platform, allowing micelle formulations of APIs, to be R&D-certified Production soluble in water – broad applications
Slide 4: Building a sustainable, profitable specialty pharma company
Building a sustainable, profitable specialty pharma company MEETING UNMET APEALEA® APPROVED A GLOBAL MEDICAL NEED IN EUROPE PARTNERSHIP IMPROVING SOLUBILITY & LEAD PRODUCT LAUNCHED WORTH UP TO $678 SIDE EFFECT PROFILS OF FOR ADVANCED OVARIAN MILLION PLUS ROYALTIES ESTABLISHED & NOVEL CANCER CANCER D
Slide 5: The new team leading Oasmia's transformation
The new team leading Oasmia’s transformation FRANCOIS MARTELET, M.D., Master’s Degree Business FREDRIK JÄRRSTEN* ELIN TRAMPE, Chief Executive Officer Chief Finance Officer Chief Technical Previous experience: Officer CEO in Biotechnology/ BioPharma in UK, DNK, US and senior executive global roles RE
Slide 6: Meeting the challenges of poor drug solubility
Meeting the challenges of poor drug solubility POOR API1 SOLUBILITY c.40% OF APPROVED A FACTOR IN SERIOUS DRUGS AFFECTED2 ADVERSE EVENTS (SAEs) MAJOR CHALLENGE IN 70-90% OF PIPELINE DRUGS SOLUBILITY ENHANCERS CAN DRUG DEVELOPMENT CLASSED AS POORLY SOLUBLE2 CAUSE SAEs AND / OR CRITICAL TO DRUG LEADIN
Slide 7: XR-17 - powerful platform that can increase solubility of insoluble compounds
XR-17™ - powerful platform that can increase solubility of insoluble compounds Active Pharmaceutical Ingredient XR-17™ XR-17™ + API (API) Hydrophilic head WATER INSOLUBLE Hydrophobic chain WATER SOLUBLE XR-17™ increases small molecule solubility and potentially improves safety and efficacy of new fo
Slide 8: XR-17 – a validated platform applicable in many therapeutic areas
XR-17™ – a validated platform applicable in many therapeutic areas Superior solubility compared with other Strong, validated safety in cancer platforms and technologies, enhances indication1 bioavailability of API Drug load capacity, enabling No mandatory or limited need for pre- high drug delivery
Slide 9: XR-17 – multiple opportunities in oncology, human and animal health
XR-17TM – multiple opportunities in oncology, human and animal health XR-17™ ANIMAL OTHER ONCOLOGY HEALTH THERAPEUTIC AREAS Lymph- Lung Cervical oma cancer cancer Masto- Prostate Breast Ovarian Bladder cytoma cancer cancer cancer cancer Docetaxel Micellar 9
Slide 10: Building a diverse portfolio based on XR-17 platform technology
Building a diverse portfolio based on XR-17™ platform technology Registration / Product Indication Pre-clinical Phase I Phase II Phase III approval Geography Human Health Portfolio Apealea® / Ovarian cancer Pre-NDA meeting USA Paclical® (paclitaxel) Ovarian cancer EU / EEA1 Technology Platform Portf
Slide 11: XR-17 – broad IP protection up to 2036
XR-17™ – broad IP protection up to 2036 PROCESS WATER-INSOLUBLE ANTICANCER COMPOSITIONS Protects the Protects poorly water- Protects XR-17™ in manufacturing process soluble APIs1 in combination combination with for XR-17™ with XR-17™ chemotherapeutic agents 56 patents granted PCT application granted
Slide 12: Apealea – offering improved treatment options
Apealea® – offering improved treatment options Approved in EU/EEA for Current standard of care in Ovarian cancer is carboplatin + paclitaxel treatment of first relapse ovarian Subset of patients cannot tolerate solvent-based paclitaxel cancer1 and in Russia for first line and relapsed Apealea® is an
Slide 13: The growing taxane market for ovarian and other cancers
The growing taxane market for ovarian and other cancers The 2018 global injectable taxane market was valued at $2.18B The market is expected to grow $4.56B by the end of 2025 (CAGR 11% 2019 – 2025) Taxol® • Paclitaxel – cremophor EL Taxotere® • Ovarian, breast, lung and Kaposi • Docetaxel – polysorb
Slide 14: Apealea - multiple benefits compared to the competition
Apealea® - multiple benefits compared to the competition Company Ovarian Cancer Ovarian Cancer Ovarian Cancer Indication Ovarian Cancer Breast Cancer Breast Cancer Breast Cancer Breast Cancer NSCLC NSCLC NSCLC Infusion Solution Micellar Solution Emulsion Colloidal Suspension Liposome Micellar Soluti
Slide 15: Apealea – meeting unmet medical needs in selected ovarian cancer
Apealea® – meeting unmet medical needs in selected ovarian cancer OVARIAN CANCER INCIDENCE1 295,000 women diagnosed 70000 66300 in 2018 – 8th most common cancer in women1 60000 50000 70% of women have a Incidence 40000 relapse three years after diagnosis2 30000 26600 24500 20000 Platinum analogs use
Slide 16: Apealea – global partnership worth up to $698m + royalties
Apealea® – global partnership worth up to $698m + royalties Agreement with US-based Elevar Therapeutics, subsidiary of South Korea’s HLB $20 M Upfront payment Double digit royalties on global % Apealea® sales Milestones based on regulatory and $678M sales achievements Oasmia retains sole control ove
Slide 17: Docetaxel micellar in clinical development
Docetaxel micellar in clinical development • Prostate cancer is a leading cause of cancer death in men worldwide • Widely approved for wide range of solid malignancies and standard of care for advanced prostate cancer • Docetaxel micellar uses XR-17™, enabling IV administration of water- insoluble c
Slide 18: Sustaining Oasmia's transformation since CEO appointment
Sustaining Oasmia’s transformation since CEO appointment • Strategic • Operational ‒ Working progress on ‒ Articulated and implemented docetaxel micellar clinical development plan incl. a collaborative agreement with ‒ Achieving Elevar deal milestones SAKK ‒ Creating revenue opportunities for the an
Slide 19: Oasmia – An investment opportunity
Oasmia – An investment opportunity • Commercial stage company with proven ability to bring promising new products to market Multiple potential near and mid-term catalysts & value drivers… • XR-17 - validated technology platform applicable across • Elevar partnering for Apealea® in Europe, range of t
Slide 20: Realising our vision for success
Solid foundations in place to build a profitable speciality pharma company Platform to build a Sweden- based cash-flow positive specialty pharma leader Realising our vision for success Well placed for M&A and licensing collaborations 20
Oasmia — Sachs 20th Annual Biotech in Europe Forum 2020 on 6ix